揭示 BCR-ABL 酪氨酸激酶抑制剂的肾毒性特征:非洲的实际经验

EJHaem Pub Date : 2024-07-31 DOI:10.1002/jha2.988
Zekarias Seifu Ayalew, Gebeyehu Tessema Azibte, Fisihatsion Tadesse, Biruk Abate Legesse, Zerubabel Getahun Kiflu, Mahlet Tsige Weldeamanuel, Kibrekidusan Aynekulu Tsige, Bereket Abraha Molla, Addisu Melkie Ejigu
{"title":"揭示 BCR-ABL 酪氨酸激酶抑制剂的肾毒性特征:非洲的实际经验","authors":"Zekarias Seifu Ayalew,&nbsp;Gebeyehu Tessema Azibte,&nbsp;Fisihatsion Tadesse,&nbsp;Biruk Abate Legesse,&nbsp;Zerubabel Getahun Kiflu,&nbsp;Mahlet Tsige Weldeamanuel,&nbsp;Kibrekidusan Aynekulu Tsige,&nbsp;Bereket Abraha Molla,&nbsp;Addisu Melkie Ejigu","doi":"10.1002/jha2.988","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The efficacy of BCR-ABL tyrosine kinase inhibitors (TKIs) in treating chronic myelogenous leukemia and other malignancies is well-documented. However, concerns about potential nephrotoxicity have raised questions. This study, conducted at Tikur Anbesa Specialized Hospital (TASH) in Addis Ababa, Ethiopia, aimed to investigate the association between TKIs and renal toxicities.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A hospital-based cross-sectional design was used to enroll 260 TASH patients actively receiving BCR-ABL TKIs. Demographic information, diagnoses, treatment details, and laboratory test results were collected for each participant's Electronic Medical Record. The primary goal was to assess adverse renal events, a combination of events of a decrease in estimated glomerular filtration rate (eGFR) exceeding 30% from baseline, significant proteinuria, and a diagnosis of acute kidney injury (AKI) or chronic kidney disease (CKD). A logistic regression model was used to analyze the data and identify factors associated with developing adverse renal events.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Our analysis revealed a statistically significant decrease in eGFR following treatment with TKIs. However, the observed rate of adverse renal events (13.1%) was lower than reported in some previous studies. Factors significantly associated with adverse renal events included longer TKI duration, male sex (protective), hypertension, HIV infection, and achieving complete molecular remission and/or a complete hematologic response. No significant associations were found with diabetes mellitus, age, angiotensin-converting enzyme inhibitors use, or baseline creatinine level.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>While this study found that BCR-ABL TKIs can lead to a decline in eGFR, AKI, and CKD, it also demonstrated that they were relatively safer in our study population.</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 4","pages":"749-756"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.988","citationCount":"0","resultStr":"{\"title\":\"Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa\",\"authors\":\"Zekarias Seifu Ayalew,&nbsp;Gebeyehu Tessema Azibte,&nbsp;Fisihatsion Tadesse,&nbsp;Biruk Abate Legesse,&nbsp;Zerubabel Getahun Kiflu,&nbsp;Mahlet Tsige Weldeamanuel,&nbsp;Kibrekidusan Aynekulu Tsige,&nbsp;Bereket Abraha Molla,&nbsp;Addisu Melkie Ejigu\",\"doi\":\"10.1002/jha2.988\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>The efficacy of BCR-ABL tyrosine kinase inhibitors (TKIs) in treating chronic myelogenous leukemia and other malignancies is well-documented. However, concerns about potential nephrotoxicity have raised questions. This study, conducted at Tikur Anbesa Specialized Hospital (TASH) in Addis Ababa, Ethiopia, aimed to investigate the association between TKIs and renal toxicities.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A hospital-based cross-sectional design was used to enroll 260 TASH patients actively receiving BCR-ABL TKIs. Demographic information, diagnoses, treatment details, and laboratory test results were collected for each participant's Electronic Medical Record. The primary goal was to assess adverse renal events, a combination of events of a decrease in estimated glomerular filtration rate (eGFR) exceeding 30% from baseline, significant proteinuria, and a diagnosis of acute kidney injury (AKI) or chronic kidney disease (CKD). A logistic regression model was used to analyze the data and identify factors associated with developing adverse renal events.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Our analysis revealed a statistically significant decrease in eGFR following treatment with TKIs. However, the observed rate of adverse renal events (13.1%) was lower than reported in some previous studies. Factors significantly associated with adverse renal events included longer TKI duration, male sex (protective), hypertension, HIV infection, and achieving complete molecular remission and/or a complete hematologic response. No significant associations were found with diabetes mellitus, age, angiotensin-converting enzyme inhibitors use, or baseline creatinine level.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>While this study found that BCR-ABL TKIs can lead to a decline in eGFR, AKI, and CKD, it also demonstrated that they were relatively safer in our study population.</p>\\n </section>\\n </div>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":\"5 4\",\"pages\":\"749-756\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.988\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.988\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.988","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

导言:BCR-ABL酪氨酸激酶抑制剂(TKIs)在治疗慢性髓性白血病和其他恶性肿瘤方面的疗效有目共睹。然而,对潜在肾毒性的担忧引发了人们的质疑。本研究在埃塞俄比亚亚的斯亚贝巴的Tikur Anbesa专科医院(TASH)进行,旨在调查TKIs与肾毒性之间的关系。 方法 采用医院横断面设计,招募了 260 名正在接受 BCR-ABL TKIs 治疗的 TASH 患者。收集了每位参与者电子病历中的人口统计学信息、诊断、治疗细节和实验室检查结果。主要目标是评估肾脏不良事件,即估计肾小球滤过率(eGFR)较基线下降超过 30%、明显蛋白尿、急性肾损伤(AKI)或慢性肾病(CKD)诊断等事件的组合。我们采用逻辑回归模型对数据进行了分析,并确定了与肾脏不良事件相关的因素。 结果 我们的分析表明,TKIs 治疗后 eGFR 有统计学意义的显著下降。然而,观察到的肾脏不良事件发生率(13.1%)低于之前的一些研究报告。与肾脏不良事件明显相关的因素包括:TKI疗程较长、男性(保护性)、高血压、HIV感染以及达到完全分子缓解和/或完全血液学反应。与糖尿病、年龄、血管紧张素转换酶抑制剂的使用或基线肌酐水平无明显关联。 结论 本研究发现,BCR-ABL TKIs 可导致 eGFR、AKI 和 CKD 下降,但同时也表明,在我们的研究人群中,BCR-ABL TKIs 相对更安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa

Introduction

The efficacy of BCR-ABL tyrosine kinase inhibitors (TKIs) in treating chronic myelogenous leukemia and other malignancies is well-documented. However, concerns about potential nephrotoxicity have raised questions. This study, conducted at Tikur Anbesa Specialized Hospital (TASH) in Addis Ababa, Ethiopia, aimed to investigate the association between TKIs and renal toxicities.

Methods

A hospital-based cross-sectional design was used to enroll 260 TASH patients actively receiving BCR-ABL TKIs. Demographic information, diagnoses, treatment details, and laboratory test results were collected for each participant's Electronic Medical Record. The primary goal was to assess adverse renal events, a combination of events of a decrease in estimated glomerular filtration rate (eGFR) exceeding 30% from baseline, significant proteinuria, and a diagnosis of acute kidney injury (AKI) or chronic kidney disease (CKD). A logistic regression model was used to analyze the data and identify factors associated with developing adverse renal events.

Results

Our analysis revealed a statistically significant decrease in eGFR following treatment with TKIs. However, the observed rate of adverse renal events (13.1%) was lower than reported in some previous studies. Factors significantly associated with adverse renal events included longer TKI duration, male sex (protective), hypertension, HIV infection, and achieving complete molecular remission and/or a complete hematologic response. No significant associations were found with diabetes mellitus, age, angiotensin-converting enzyme inhibitors use, or baseline creatinine level.

Conclusions

While this study found that BCR-ABL TKIs can lead to a decline in eGFR, AKI, and CKD, it also demonstrated that they were relatively safer in our study population.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信